

IFW

UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

MATSUZAKI, Koichi, et al.

Group Art Unit: Not Yet Assigned

Serial No.: 10/822,860

Examiner: Not Yet Assigned

Filed: April 13, 2004

For: ANTIBODIES SPECIFIC FOR PHOSPHORYLATION SITES AND
SCREENING METHODS USING THE SAME ANTIBODIES

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 7, 2004

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.

No fee is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.


The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

Serial No.: 10/822,860

The Commissioner is authorized to charge our Deposit Account No. 01-2340 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

ARMSTRONG, KRATZ, QUINTOS, HANSON & BROOKS, LLP

 : Reg. No. 22,631
for Donald W. Hanson
Attorney for Applicants
Reg. No. 27,133


Atty. Docket No. 040176
Suite 1000, 1725 K Street, N.W.
Washington, D.C. 20006
(202) 659-2930
DWH/nk



23850

PATENT TRADEMARK OFFICE

Enclosures: PTO1449, 13 References



INFORMATION DISCLOSURE CITATION PTO-1449	Atty. Docket No. 040176	Serial No. 10/822,860
	Applicant(s): MATSUZAKI, Koichi, et al.	
	Filing Date: April 13, 2004	Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Sub class	Filing Date (If appropriate)
_____	AA					
_____	AB					

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Translation (Yes or No)
_____	AC		
_____	AD		

OTHER DOCUMENTS

_____	AE	Lindemann et al; "Interfering with TGF β -induced Smad3 nuclear accumulation differentially affects TGF β -dependent gene expression"; Molecular Cancer 2003; 2:20; pp1-10.
_____	AF	Wang et al; "Requirement of Mitogen-activated Protein Kinase Kinase 3in Murine Mesangial Cells"; J. Biological Chemistry; 2002; 277:49 pp47257-47262.
_____	AG	Leioven et al; "Smad3 Mediates Transforming Growth Factor- β -induced Collagenase-3 Fibroblasts" J. Biological Chemistry; 2002; 277:48; pp46338-45346.
_____	AH	Bakin et al; "p38 mitogen-activated protein kinase is required for TGF- β -mediated fibroblastic transdifferentiation and cell migration;" J. Cell Science 2002; 115, pp3192-3206.
_____	AI	Tahashi et al; "Differential Regulation of TGF- β Signal inRat Liver Injury;" American Association for Liver Studies; 2002; pp 49-61.
_____	AJ	Matsuzaki et al; "Modulation of transforming growth factor β function in hepatocytes and hepatic stellate cells in rat liver injury;" GUT, May 2000; 46:3; pp 719-724.
_____	AK	Matsuzaki et al; "Regulatory Mechanisms for Transforming Growth Factor β as an Autocrine Inhibitorin Its Growth;" American Association for Liver Studies 2000; pp218-227.
_____	AL	Matsuzaki et al; "Autocrine Stimulatory Mechanism by Transforming Growth Factor β in Human Hepatocellular Carcinoma"; Cancer Research 60; March 1 2000; pp 1394-1402.
_____	AM	Ravanti et al; "Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor- β via p38 mitogen-activated protein kinase;" FASEB J. 10-1096; published online February 20, 2001.
_____	AN	Moustakas et al; "Smad regulation in TGF- β signal transduction"; J. Cell Science 2001; 113; pp 4359-4369.
_____	AO	Date et al; "Differential expression of transforming growth factor- β and its receptors in hepatocytes and nonparenchymal cells of rat liver after CCl ₄ administration"; J. Hepatology 1998; 28: pp 572-581.
_____	AP	Heldin et al; "TGF- β signalling from cell membrane to nucleus through SMAD proteins." Nature (December 1997); 390:4; pp465-471.(see spec. page 2).
_____	AQ	Kretschmar et al; "Opposing BMP and EGF signalling pathways converge on the TGF- β family mediator Smad-1;" Nature (October 1997) 389:9; pp 618-622.

Examiner	Date Considered
----------	-----------------